SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02194049

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer

This phase I trial studies the side effects and the best dose of PI3K inhibitor BKM120 when given together with cisplatin and etoposide in treating patients with advanced solid tumors or small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing , or by stopping them from spreading. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving PI3K inhibitor BKM120 with cisplatin and etoposide may kill more tumor cells.

NCT02194049 Extensive Stage Small Cell Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific
MeSH: Lung Neoplasms Small Cell Lung Carcinoma
HPO: Neoplasm of the lung Small cell lung carcinoma

3 Interventions

Name: BKM120

Description: Given PO

Type: Drug

BKM 120, cisplatin, etoposide

Name: cisplatin

Description: Given IV

Type: Drug

BKM 120, cisplatin, etoposide

Name: etoposide

Description: Given IV

Type: Drug

BKM 120, cisplatin, etoposide


Primary Outcomes

Description: The toxicities observed at each dose level will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity, time of onset (i.e. course number), duration, and reversibility or outcome.

Measure: Incidence of adverse events of combining daily BKM120 with cisplatin and etoposide as graded by the National Cancer Institute (NC) CTCAE version 4.0

Time: Up to 28 days post-treatment

Secondary Outcomes

Description: The toxicities observed at each dose level will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity, time of onset (i.e. course number), duration, and reversibility or outcome.

Measure: MTD defined as the highest dose tested in which fewer than 33% of patients experience DLT attributed to the study drugs when at least 6 patients were treated at that dose, as graded by NCI CTCAE version 4.0

Time: 21 days

Description: Response rate among patients with measurable disease will be summarized by exact binomial confidence intervals

Measure: Response rate assessed by computed tomography (CT) scan based on Response Evaluation Criteria In Solid Tumors (RECIST)

Time: Up to 30 days

Description: Survival will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. Median survival time will be estimated using standard life table methods.

Measure: Overall survival

Time: Up to 30 days

Description: TTP will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. Median time to progression will be estimated using standard life table methods.

Measure: Time to progression (TTP) based on RECIST

Time: Up to 30 days

Description: Pharmacokinetic analysis will use non-linear curve fitting methods to estimate the mean peak concentration.

Measure: Pharmacokinetic analysis

Time: Baseline, at 1, 2, 4, 6, and 24 hours of day 1 of course 1, baseline day 15 of course 1, and at 1 and 2 hours post-dose on day 1 of course 2

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 P13K

Pharmacokinetic analysis will use non-linear curve fitting methods to estimate the mean peak concentration.. Inclusion Criteria: - Histological or cytological proven advanced solid tumors - =< 3 chemotherapy regimens for metastatic disease; any number of prior targeted or biologic therapies is allowed; (in the expansion cohort, patients must be chemo naïve) - ECOG performance status =< 2 - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - Hemoglobin (Hb) > 9 g/dL - Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed) - Magnesium >= the lower limit of normal - Potassium within normal limits for the institution - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal (ULN) if liver metastases are present) - Serum bilirubin within normal range (or =< 1.5 x ULN if liver metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) - Serum creatinine =< 1.5 x ULN or calculated clearance >= 60 mL/min - Serum albumin >= 3 g/dl - Serum amylase =< ULN - Serum lipase =< ULN - Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L) - International normalized ratio (INR) =< 2 - Ability to swallow pills - Negative serum pregnancy test Exclusion Criteria: - Received prior treatment with a P13K inhibitor - Received > 300 mg/m^2 of cisplatin and/or for whom cisplatin would not be beneficial - Prior treatment with any investigational drug within the preceding 3 weeks - Known hypersensitivity to BKM120 or to its excipients - Untreated brain metastases are excluded - Acute or chronic liver, renal disease or pancreatitis - Following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire - Diarrhea >= CTCAE grade 2 - Active cardiac disease - History of cardiac dysfunction - Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus - Other concurrent severe and/or uncontrolled concomitant medical conditions - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated - Treated with any hematopoietic colony-stimulating growth factors - Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug - Chronic treatment with steroids or another immunosuppressive agent - Herbal medications and certain fruits within 7 days prior to starting study drug - Treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug - Intravenous chemotherapy or targeted anticancer therapy =< 4 weeks - Any continuous or intermittent oral small molecule therapeutics - Received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant - Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control - Known diagnosis of HIV infection - History of another active malignancy - Unable or unwilling to abide by the study protocol or cooperate fully with the investigator treatments Inclusion Criteria: - Histological or cytological proven advanced solid tumors - =< 3 chemotherapy regimens for metastatic disease; any number of prior targeted or biologic therapies is allowed; (in the expansion cohort, patients must be chemo naïve) - ECOG performance status =< 2 - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - Hemoglobin (Hb) > 9 g/dL - Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed) - Magnesium >= the lower limit of normal - Potassium within normal limits for the institution - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal (ULN) if liver metastases are present) - Serum bilirubin within normal range (or =< 1.5 x ULN if liver metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) - Serum creatinine =< 1.5 x ULN or calculated clearance >= 60 mL/min - Serum albumin >= 3 g/dl - Serum amylase =< ULN - Serum lipase =< ULN - Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L) - International normalized ratio (INR) =< 2 - Ability to swallow pills - Negative serum pregnancy test Exclusion Criteria: - Received prior treatment with a P13K inhibitor - Received > 300 mg/m^2 of cisplatin and/or for whom cisplatin would not be beneficial - Prior treatment with any investigational drug within the preceding 3 weeks - Known hypersensitivity to BKM120 or to its excipients - Untreated brain metastases are excluded - Acute or chronic liver, renal disease or pancreatitis - Following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire - Diarrhea >= CTCAE grade 2 - Active cardiac disease - History of cardiac dysfunction - Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus - Other concurrent severe and/or uncontrolled concomitant medical conditions - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated - Treated with any hematopoietic colony-stimulating growth factors - Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug - Chronic treatment with steroids or another immunosuppressive agent - Herbal medications and certain fruits within 7 days prior to starting study drug - Treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug - Intravenous chemotherapy or targeted anticancer therapy =< 4 weeks - Any continuous or intermittent oral small molecule therapeutics - Received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant - Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control - Known diagnosis of HIV infection - History of another active malignancy - Unable or unwilling to abide by the study protocol or cooperate fully with the investigator treatments Extensive Stage Small Cell Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Lung Neoplasms Small Cell Lung Carcinoma PRIMARY OBJECTIVES: I. To determine the safety and feasibility of combining BKM120 (PI3K inhibitor BKM120) with cisplatin and etoposide in advanced solid tumors, with emphasis on small cell lung cancer (SCLC). --- P13K ---

Pharmacokinetic analysis will use non-linear curve fitting methods to estimate the mean peak concentration.. Inclusion Criteria: - Histological or cytological proven advanced solid tumors - =< 3 chemotherapy regimens for metastatic disease; any number of prior targeted or biologic therapies is allowed; (in the expansion cohort, patients must be chemo naïve) - ECOG performance status =< 2 - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - Hemoglobin (Hb) > 9 g/dL - Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed) - Magnesium >= the lower limit of normal - Potassium within normal limits for the institution - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal (ULN) if liver metastases are present) - Serum bilirubin within normal range (or =< 1.5 x ULN if liver metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) - Serum creatinine =< 1.5 x ULN or calculated clearance >= 60 mL/min - Serum albumin >= 3 g/dl - Serum amylase =< ULN - Serum lipase =< ULN - Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L) - International normalized ratio (INR) =< 2 - Ability to swallow pills - Negative serum pregnancy test Exclusion Criteria: - Received prior treatment with a P13K inhibitor - Received > 300 mg/m^2 of cisplatin and/or for whom cisplatin would not be beneficial - Prior treatment with any investigational drug within the preceding 3 weeks - Known hypersensitivity to BKM120 or to its excipients - Untreated brain metastases are excluded - Acute or chronic liver, renal disease or pancreatitis - Following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire - Diarrhea >= CTCAE grade 2 - Active cardiac disease - History of cardiac dysfunction - Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus - Other concurrent severe and/or uncontrolled concomitant medical conditions - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated - Treated with any hematopoietic colony-stimulating growth factors - Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug - Chronic treatment with steroids or another immunosuppressive agent - Herbal medications and certain fruits within 7 days prior to starting study drug - Treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug - Intravenous chemotherapy or targeted anticancer therapy =< 4 weeks - Any continuous or intermittent oral small molecule therapeutics - Received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant - Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control - Known diagnosis of HIV infection - History of another active malignancy - Unable or unwilling to abide by the study protocol or cooperate fully with the investigator treatments Inclusion Criteria: - Histological or cytological proven advanced solid tumors - =< 3 chemotherapy regimens for metastatic disease; any number of prior targeted or biologic therapies is allowed; (in the expansion cohort, patients must be chemo naïve) - ECOG performance status =< 2 - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - Hemoglobin (Hb) > 9 g/dL - Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed) - Magnesium >= the lower limit of normal - Potassium within normal limits for the institution - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal (ULN) if liver metastases are present) - Serum bilirubin within normal range (or =< 1.5 x ULN if liver metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) - Serum creatinine =< 1.5 x ULN or calculated clearance >= 60 mL/min - Serum albumin >= 3 g/dl - Serum amylase =< ULN - Serum lipase =< ULN - Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L) - International normalized ratio (INR) =< 2 - Ability to swallow pills - Negative serum pregnancy test Exclusion Criteria: - Received prior treatment with a P13K inhibitor - Received > 300 mg/m^2 of cisplatin and/or for whom cisplatin would not be beneficial - Prior treatment with any investigational drug within the preceding 3 weeks - Known hypersensitivity to BKM120 or to its excipients - Untreated brain metastases are excluded - Acute or chronic liver, renal disease or pancreatitis - Following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire - Diarrhea >= CTCAE grade 2 - Active cardiac disease - History of cardiac dysfunction - Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus - Other concurrent severe and/or uncontrolled concomitant medical conditions - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated - Treated with any hematopoietic colony-stimulating growth factors - Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug - Chronic treatment with steroids or another immunosuppressive agent - Herbal medications and certain fruits within 7 days prior to starting study drug - Treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug - Intravenous chemotherapy or targeted anticancer therapy =< 4 weeks - Any continuous or intermittent oral small molecule therapeutics - Received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant - Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control - Known diagnosis of HIV infection - History of another active malignancy - Unable or unwilling to abide by the study protocol or cooperate fully with the investigator treatments Extensive Stage Small Cell Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Lung Neoplasms Small Cell Lung Carcinoma PRIMARY OBJECTIVES: I. To determine the safety and feasibility of combining BKM120 (PI3K inhibitor BKM120) with cisplatin and etoposide in advanced solid tumors, with emphasis on small cell lung cancer (SCLC). --- P13K --- --- P13K ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Small cell lung carcinoma